Ruiz Hurtado, Gema Fernández Alfonso, María S. Ruilope Urioste, Luis Miguel
Global cardiovascular protection in chronic kidney disease. [revisión] - Nature reviews. Cardiology, 2016 - 13(10):603-8.
Formato Vancouver:
Ruiz Hurtado G, Sarafidis P, Fernández Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol. 2016 Oct;13(10):603-8.
PMID: 27053454
Contiene 87 referencias
The development and progression of cardiovascular disease (CVD) and renal disorders are very closely related. In patients with chronic kidney disease (CKD), therapies proven to protect the cardiovascular and renal systems simultaneously are generally used only at low doses or not at all. In particular, patients with CKD who receive angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, or mineralocorticoid-receptor antagonists (MRAs) often do not experience complete blockade of the renin-angiotensin-aldosterone system, primarily owing to the risk of hyperkalaemia. In this Review, we provide an overview of the available treatments required for adequate cardiorenal protection in patients with CKD. Drugs such as β-blockers that interfere with renin secretion will be discussed, in addition to agents that can prevent hyperkalaemia, such as potassium binders and nonsteroidal MRAs. Furthermore, the current literature on the role of statins, in addition to new compounds and dosing recommendations for the treatment of patients with CKD will also be reviewed. Further studies with these new compounds and doses are needed to ascertain whether these approaches can improve the long-term cardiovascular and renal prognosis in patients with CKD.
Global cardiovascular protection in chronic kidney disease. [revisión] - Nature reviews. Cardiology, 2016 - 13(10):603-8.
Formato Vancouver:
Ruiz Hurtado G, Sarafidis P, Fernández Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol. 2016 Oct;13(10):603-8.
PMID: 27053454
Contiene 87 referencias
The development and progression of cardiovascular disease (CVD) and renal disorders are very closely related. In patients with chronic kidney disease (CKD), therapies proven to protect the cardiovascular and renal systems simultaneously are generally used only at low doses or not at all. In particular, patients with CKD who receive angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, or mineralocorticoid-receptor antagonists (MRAs) often do not experience complete blockade of the renin-angiotensin-aldosterone system, primarily owing to the risk of hyperkalaemia. In this Review, we provide an overview of the available treatments required for adequate cardiorenal protection in patients with CKD. Drugs such as β-blockers that interfere with renin secretion will be discussed, in addition to agents that can prevent hyperkalaemia, such as potassium binders and nonsteroidal MRAs. Furthermore, the current literature on the role of statins, in addition to new compounds and dosing recommendations for the treatment of patients with CKD will also be reviewed. Further studies with these new compounds and doses are needed to ascertain whether these approaches can improve the long-term cardiovascular and renal prognosis in patients with CKD.
